Frankel, Paul

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine

Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Cited by 515

Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Ebrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 109

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., et al. (2018) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentImmunotherapy and Immune Responses

Cited by 66

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Siddiqi, T., Frankel, P., Beumer, J. H., Kiesel, B. F., Christner, S., Ruel, C., Song, J. Y., Chen, R., Kelly, K. R., Ailawadhi, S., et al. (2020) · Leukemia & Lymphoma

Lymphoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia research

Cited by 30

Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.

Koczywas, M., Frankel, P. H., Riess, J. W., El-Khoueiry, A. B., Villaruz, L. C., Leong, S., Ruel, C., Synold, T. W., O'Connor, T., & Newman, E. M. (2020) · Journal of Clinical Oncology

Occupational and environmental lung diseasesCancer therapeutics and mechanisms

Cited by 2